The discovery of EGFR-activating mutations as a predictor of patient response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) represented a milestone and paradigm shift in the treatment of non–small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.